Extended-dose DOAC vs full-dose DOAC #Renove trial #ASH24 Late breaking abstract. Officially, reduced dose was not non-inferior, but recurrent #VTE rates were low and there is a substantial reduction in major and non-major bleeding. Congratulations to the French colleagues of #Innovte!